Promising Safety and Efficacy of BAFF-R CAR T-Cell Therapy in B-Cell Lymphomas to Be Presented at EHA 2026

PeproMene Bio Unveils Promising Findings on PMB-CT01

PeproMene Bio, a biotechnology firm based in Irvine, California, has made headlines with its latest announcement regarding PMB-CT01, an innovative CAR T-cell therapy specifically targeting B-cell lymphomas. The clinical data from the ongoing Phase 1 trial has been selected for an oral presentation at the prestigious 2026 Congress of the European Hematology Association (EHA), a key event for professionals in the field.

Overview of the Presentation

The presentation will delve into the latest findings from the dose-escalation phase of the study, focusing on patients diagnosed with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). Distinctively, this includes individuals whose cancer has not responded to conventional CD19-directed CAR T-cell therapies, a significant population facing a dire lack of treatment options.

Among the nine patients evaluated in this crucial phase, the results have been striking. PMB-CT01 exhibited an excellent safety profile: no dose-limiting toxicities were recorded, with all cases of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) remaining at grade 1 or below. Impressively, seven out of nine patients (78%) attained a complete response (CR), and none of them experienced relapses. Some participants have maintained their responses for over three years, a noteworthy duration for cancer treatments. Furthermore, patients who responded achieved minimal residual disease (MRD)-negative status, underscoring the significant remission of detectable cancer cells.

Future Directions

Encouraged by these results, PeproMene Bio is actively expanding the trial to include cohorts for further malignancies such as mantle cell lymphoma, large B-cell lymphoma, and follicular lymphoma. The company highlighted a particularly encouraging case where the first patient treated in this expansion phase - an individual with transformed follicular lymphoma (tFL) who had previously failed CD19 CAR T therapy - achieved a CR at the first disease assessment. tFL is noted for its aggressive nature and limited treatment alternatives, making this development even more significant.

Dr. Larry W. Kwak, M.D., Ph.D., the scientific founder of PeproMene Bio, emphasizes the importance of PMB-CT01's results. He stated, "When cancer progresses following CD19 CAR T therapy, patients encounter a substantial unmet medical need, leading to limited therapeutic avenues. The durable complete responses we are witnessing validate BAFF-R as a promising new target. The favorable safety profile could facilitate PMB-CT01’s application in outpatient community oncology settings and pave the way for investigations into refractory autoimmune conditions."

Presentation Details

The presentation titled "Durable responses and favorable safety of BAFF-R CAR T-cells (PMB-CT01) in patients with relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease" is scheduled for June 14, 2026, from 11:00 AM to 12:15 PM CEST, featuring Dr. Larry W. Kwak as the presenter.

About PMB-CT01

PMB-CT01 represents a pioneering approach in CAR T-cell therapy, utilizing a target (BAFF-R) that is predominantly expressed on B cells, thus bolstering the persistence of the therapy and lowering the likelihood of antigen-loss escape. This distinctive targeting feature is integral to its potential effectiveness in treating resistant B-cell malignancies.

About PeproMene Bio

PeproMene Bio, Inc. is at the forefront of innovation within the clinical-stage biopharmaceutical sector, focusing on the development of groundbreaking therapies aimed at combating cancers and immune disorders. For further information, Hazel Cheng, Ph.D., COO of PeproMene Bio, can be contacted via email protected] or visit [PeproMene Bio's website.

Conclusion

PeproMene Bio's advances in CAR T-cell therapy for B-cell lymphomas herald a potentially transformative shift in treatment paradigms. The insights shared at EHA 2026 may inspire hope for patients and practitioners alike, signaling a step forward in battling complex hematological malignancies.